16 / 188
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
Version2.2015, 03/11/2015© National Comprehensive Cancer Network, Inc. 2015,All rights reserved.The NCCN Guidelines
®
and this illustration may not be reproduced in any form without the express written permission of NCCN
®
.
Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
BINV-4
NCCN Guidelines Version 2.2015
Invasive Breast Cancer
b
See Principles of HER2 Testing (BINV-A)
.
u
This includes medullary and micropapillary subtypes.
HISTOLOGY
HORMONE
RECEPTOR STATUS
HER2 STATUS
SYSTEMIC ADJUVANT TREATMENT
• Ductal
u
• Lobular
• Mixed
• Metaplastic
• Tubular
• Mucinous
ER positive
and/or
PR positive
ER negative
and
PR negative
ER positive
and/or
PR positive
ER negative
and
PR negative
HER2-positive
b
HER2-negative
b
HER2-positive
b
HER2-negative
b
See Systemic Adjuvant Treatment -
Favorable Histologies (BINV-9)
See Systemic Adjuvant Treatment - Hormone Receptor
Positive - HER2-Positive Disease (BINV-5)
See Systemic Adjuvant Treatment - Hormone
Receptor Positive - HER2-Negative Disease (BINV-6)
See Systemic Adjuvant Treatment - Hormone
Receptor Negative - HER2-Positive Disease (BINV-7)
See Systemic Adjuvant Treatment - Hormone
Receptor Negative - HER2-Negative Disease (BINV-8)